MILLENNIUM HEALTHCARE CEO REPORTS ON OPERATIONAL DEVELOPMENTS AND PROGRESS

Millennium Healthcare Inc. (OTCBB: MHCC) today issued a statement from its Chief Executive Officer, Dominick Sartorio, providing an update on recent corporate developments. The statement is included in its entirety below:

Millennium Medical Devices has begun the official launch of its current product lines. The product launch marks the conclusion of product beta testing and the initiation and development of product roll out and revenues for the Company. The Company is now focused on product distribution, execution, and training for the previously announced 1,300 locations now in our distribution network through various network selling agreements.

Beta testing for product usage was completed through June with a soft product roll out and revenue capture beginning in July. Beta testing proved to be a great success and has provided the Company with valuable training information along with product acceptance, implementation and usage data. Beta testing for OralCDx and Vasoscan was conducted in selected locations on the East Coast.

With product rollout initially launched in five states, David Perry, Millennium Chief Operating Officer stated, “Recently, a Millennium Healthcare team was dispatched for product implementation comprised of a key physician, a medical assistant and a certified representative, which, collectively executed the Company’s first round of installations with outstanding results.” Mr. Perry continued, “With the conclusion of the beta test phase for our first two products, OralCDx, an oral cancer biopsy test and Vasoscan, a cardiovascular diagnostic assessment test, initial usage levels have exceeded our internal expectations. Vasoscan testing done in physician offices during beta testing were at an average 19.7 tests per day per office. The soft launch of the OralCDx product within our network averaged initial physician stocking orders of 100 kits per location with an average reorder rate of 92%. This demonstrates a high level of adoption and integration of the OralCDx technology.”